Total Payments
$2,981
2022 Payments
$1,278
Companies
9
Transactions
26
Medicare Patients
635
Medicare Billing
$137,877
Payment Breakdown by Category
Consulting$1,278 (42.9%)
Other$1,208 (40.5%)
Food & Beverage$494.89 (16.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,278 | 1 | 42.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,208 | 1 | 40.5% |
| Food and Beverage | $494.89 | 24 | 16.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic, Inc. | $1,278 | 1 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $1,208 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $242.39 | 11 | $0 (2019) |
| Exelixis Inc. | $75.92 | 4 | $0 (2019) |
| Amgen Inc. | $65.19 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $36.65 | 2 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $35.82 | 2 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $23.06 | 1 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $15.86 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,278 | 1 | Medtronic, Inc. ($1,278) |
| 2020 | $15.52 | 1 | AstraZeneca Pharmaceuticals LP ($15.52) |
| 2019 | $1,331 | 7 | SANOFI-AVENTIS U.S. LLC ($1,208) |
| 2018 | $230.16 | 11 | E.R. Squibb & Sons, L.L.C. ($133.72) |
| 2017 | $126.70 | 6 | E.R. Squibb & Sons, L.L.C. ($65.05) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/09/2022 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,278.00 | General |
| 01/13/2020 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Oncology | ||||||
| 09/12/2019 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,208.00 | General |
| 09/09/2019 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Hematology | ||||||
| 08/12/2019 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug), Nexavar | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: Oncology | ||||||
| 07/08/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: Oncology | ||||||
| 06/10/2019 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Oncology | ||||||
| 03/13/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.21 | General |
| Category: Oncology | ||||||
| 02/25/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $24.41 | General |
| Category: Oncology | ||||||
| 11/27/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: Oncology | ||||||
| 11/14/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.16 | General |
| Category: Oncology | ||||||
| 11/12/2018 | Otsuka America Pharmaceutical, Inc. | SPRYCEL (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: HEMATOLOGY | ||||||
| 10/22/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $27.26 | General |
| Category: Oncology | ||||||
| 09/10/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.26 | General |
| Category: Oncology | ||||||
| 08/13/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Oncology | ||||||
| 07/23/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.55 | General |
| Category: Oncology | ||||||
| 07/09/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.77 | General |
| Category: Oncology | ||||||
| 05/09/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.72 | General |
| Category: Oncology | ||||||
| 04/09/2018 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Oncology | ||||||
| 01/08/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Oncology | ||||||
| 12/11/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.07 | General |
| Category: Oncology | ||||||
| 08/14/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.96 | General |
| Category: Oncology | ||||||
| 06/27/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Oncology | ||||||
| 06/12/2017 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Hematology | ||||||
| 04/24/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.02 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 125 | 158 | $73,875 | $20,057 |
| 2022 | 5 | 119 | 161 | $76,500 | $21,584 |
| 2021 | 8 | 164 | 202 | $149,900 | $34,615 |
| 2020 | 8 | 227 | 277 | $237,050 | $61,621 |
Total Patients
635
Total Services
798
Medicare Billing
$137,877
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 65 | $19,500 | $6,774 | 34.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 29 | $17,400 | $5,189 | 29.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $9,000 | $3,466 | 38.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $9,450 | $3,084 | 32.6% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2023 | 19 | 19 | $18,525 | $1,545 | 8.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 21 | 41 | $24,600 | $7,569 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 41 | 63 | $18,900 | $7,070 | 37.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $7,875 | $3,051 | 38.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $8,550 | $2,874 | 33.6% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2022 | 17 | 17 | $16,575 | $1,020 | 6.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 68 | $20,400 | $7,309 | 35.8% |
| 32650 | Adhesion of the lung linings using an endoscope | Facility | 2021 | 12 | 12 | $30,000 | $6,837 | 22.8% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 21 | 33 | $19,800 | $5,965 | 30.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 24 | $10,800 | $4,160 | 38.5% |
| 39010 | Drainage, biopsy, or removal of foreign body of chest cavity, transthoracic, with sternotomy | Facility | 2021 | 11 | 12 | $18,000 | $4,023 | 22.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $7,025 | $2,851 | 40.6% |
| 32550 | Insertion of permanent catheter for drainage of lung fluid | Facility | 2021 | 13 | 13 | $23,400 | $2,326 | 9.9% |
| 31622 | Diagnostic examination of lung airways using an endoscope | Facility | 2021 | 19 | 21 | $20,475 | $1,143 | 5.6% |
| 32669 | Removal of a segment of lung tissue using an endoscope | Facility | 2020 | 19 | 19 | $87,400 | $21,147 | 24.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 36 | 57 | $34,200 | $11,120 | 32.5% |
| 39010 | Drainage, biopsy, or removal of foreign body of chest cavity | Facility | 2020 | 24 | 24 | $36,000 | $9,082 | 25.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 59 | 86 | $25,800 | $8,206 | 31.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 25 | 26 | $11,050 | $4,610 | 41.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 24 | 24 | $8,400 | $3,512 | 41.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $4,950 | $2,018 | 40.8% |
About Dr. Christopher Cua, MD
Dr. Christopher Cua, MD is a Specialist healthcare provider based in Jamaica Plain, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1497736474.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Cua, MD has received a total of $2,981 in payments from pharmaceutical and medical device companies, with $1,278 received in 2022. These payments were reported across 26 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($1,278).
As a Medicare-enrolled provider, Cua has provided services to 635 Medicare beneficiaries, totaling 798 services with total Medicare billing of $137,877. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Jamaica Plain, MA
- Active Since 11/08/2005
- Last Updated 07/08/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1497736474
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $1,208
- OPDIVO (Biological) $217.98
- Cabometyx (Drug) $75.92
- Nplate (Biological) $43.62
- SPRYCEL (Drug) $35.82
- EMPLICITI (Biological) $24.41
- Stivarga (Drug) $23.06
- Neulasta (Biological) $21.57
- FASLODEX (Drug) $21.13
- Imbruvica (Drug) $15.86
- LYNPARZA (Drug) $15.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.